Loading
CD19 t-haNK is an experimental cell therapy whose type is not stated from ImmunityBio in phase 2 trials for hodgkin lymphoma, aimed at CD19.
CD19 t-haNK is a cell therapy whose type is not stated developed by ImmunityBio. Its target is CD19 (the sponsor names CD19). The sponsor states: CD19-targeted natural killer (haNK) cell therapy intended to bind CD19 on malignant B cells and drive immune-mediated cell death; studied in combination with the IL-15 superagonist N-803 (nogapendekin alfa inbakicept) and rituximab. ClinicalTrials.gov describes the intervention as: N-803 Subcutaneous (SQ): N-803 is a novel IL-15 superagonist immunotherapy administered subcutaneously. It is designed to enhance the proliferation and activation of natural killer (NK) cells and CD8+ T cells without stimulating regulatory. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in hodgkin lymphoma. The largest, NCT07125872, plans to enrol 20 participants with primary completion expected 2027-05-25. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
CD19-targeted natural killer (haNK) cell therapy intended to bind CD19 on malignant B cells and drive immune-mediated cell death; studied in combination with the IL-15 superagonist N-803 (nogapendekin alfa inbakicept) and rituximab. Connects to CD19.
1.CD19 t-haNK slips into a pocket on CD19.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"CD19 t-haNK" OR ABSTRACT:"CD19 t-haNK") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD19 t-haNK, not a curated reading list.
Shares CD19, Hodgkin lymphoma and the tag pipeline.
Shares ImmunityBio and the tag pipeline.
Shares CD19, Hodgkin lymphoma and the tag pipeline.
Shares CD19, Hodgkin lymphoma and the tag pipeline.
Shares ImmunityBio and the tag pipeline.
Shares CD19 and the tag pipeline.
Shares ImmunityBio and the tag pipeline.
Shares ImmunityBio and the tag pipeline.